Program
anbenitamab repodatecan
Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Stomach Neoplasms · Ovarian Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alphamab Oncology | 43 open or running | phase 3since Sep 22, 2023 | Aug 4, 2022 | Dec 30, 2026phase 3 · NCT06751485 |
| CSPC Pharmaceutical Group | 44 open or running | phase 3since Jan 6, 2025 | Jan 6, 2025 | May 29, 2027phase 2 · NCT07545044 |
- Named in CSPC Pharmaceutical Group’s own pipeline as
anbenitamab repodatecan (JSKN003)
, phase 3, as of Aug 20, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseCSPC (JMT-Bio) licensed it from Alphamab, for mainland China, in cancer.Announced Sep 30, 2024 · Source: Alphamab Oncology (release), Sep 30, 2024
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.
- Aug 4, 2022First study: phase 1 study in Advanced Solid TumorsNew to Alphamab OncologyAlphamab Oncology · NCT05494918 · 62 enrolled · Australia
- Jan 10, 2023Phase 2 study in Advanced Solid TumorAlphamab Oncology · NCT05744427 · 725 enrolled · China
- Sep 22, 2023Phase 3 study in Breast NeoplasmsAlphamab Oncology · NCT06079983 · 400 planned · China
- Sep 30, 2024CSPC (JMT-Bio) licensed it from AlphamabLicenseMainland China, in cancer · announced · Alphamab Oncology (release)
- Dec 25, 2024Phase 3 study in Ovarian NeoplasmsAlphamab Oncology · NCT06751485 · 430 planned
- Jan 6, 2025CSPC Pharmaceutical Group’s first study: phase 3 study in Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer ParticipantsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06846437 · 228 planned · China
- May 12, 2025Phase 2 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT06998771 · 153 planned
- Jan 26, 2026Phase 3 study in HER2-positive Colorectal CancerCSPC Pharmaceutical Group · NCT07384377 · 123 planned
- Apr 15, 2026Phase 2 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT07545044 · 60 planned
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Ovarian NeoplasmsAlphamab Oncology · NCT06751485
- May 29, 2027Primary completion: phase 2 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT07545044
- Nov 30, 2027Primary completion: phase 3 study in HER2-positive Colorectal CancerCSPC Pharmaceutical Group · NCT07384377
- Jun 30, 2028Primary completion: phase 2 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT06998771
TargetBeta
“An antibody-drug conjugate (ADC) composed of the bispecific monoclonal antibody anbenitamab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2)…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of the bispecific monoclonal antibody anbenitamab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), s”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07545044Breast Neoplasms | 2 | Not yet recruiting | CSPC Pharmaceutical Group | May 29, 2027 | 60 |
| NCT07384377HER2-positive Colorectal Cancer | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Nov 30, 2027 | 123 |
| NCT06998771HER2-positive Gastric Cancer | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Jun 30, 2028 | 153 |
| NCT06846437Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants · China | 3 | Recruiting | CSPC Pharmaceutical Group | Oct 13, 2026 | 228 |
| NCT06751485Ovarian Neoplasms | 3 | Not yet recruiting | Alphamab Oncology | Dec 30, 2026 | 430 |
| NCT06079983Breast Neoplasms · China | 3 | Recruiting | Alphamab Oncology | Apr 1, 2026 | 400 |
| NCT05744427Advanced Solid Tumor · China | 2 | Active, not recruiting | Alphamab Oncology | Jul 30, 2026 | 725 |
| NCT05494918Advanced Solid Tumors · Australia | 1 | Completed | Alphamab Oncology | Apr 15, 2025 | 62 |
How it is read
Names in the registry
- “JSKN003”, 8 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 3 studies
- Colorectal Neoplasms, 1 study
- Stomach Neoplasms, 1 study
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.